OssDsign 관리

관리 기준 확인 2/4

OssDsign CEO는 Morten Henneveld, Sep2020 에 임명되었습니다 의 임기는 4.17 년입니다. 총 연간 보상은 SEK 7.94M, 54% 로 구성됩니다. 54% 급여 및 46% 보너스(회사 주식 및 옵션 포함). 는 € 144.93K 가치에 해당하는 회사 주식의 0.2% 직접 소유합니다. 144.93K. 경영진과 이사회의 평균 재임 기간은 각각 4 년과 5.8 년입니다.

주요 정보

Morten Henneveld

최고 경영자

SEK 7.9m

총 보상

CEO 급여 비율	54.0%
CEO 임기	4.2yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	4yrs
이사회 평균 재임 기간	5.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Morten Henneveld 의 보수는 OssDsign 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-SEK 90m
Jun 30 2024	n/a	n/a	-SEK 114m
Mar 31 2024	n/a	n/a	-SEK 118m
Dec 31 2023	SEK 8m	SEK 4m	-SEK 130m
Sep 30 2023	n/a	n/a	-SEK 109m
Jun 30 2023	n/a	n/a	-SEK 95m
Mar 31 2023	n/a	n/a	-SEK 99m
Dec 31 2022	SEK 6m	SEK 4m	-SEK 99m
Sep 30 2022	n/a	n/a	-SEK 96m
Jun 30 2022	n/a	n/a	-SEK 93m
Mar 31 2022	n/a	n/a	-SEK 95m
Dec 31 2021	SEK 6m	SEK 6m	-SEK 94m
Sep 30 2021	n/a	n/a	-SEK 90m
Jun 30 2021	n/a	n/a	-SEK 92m
Mar 31 2021	n/a	n/a	-SEK 90m
Dec 31 2020	SEK 1m	SEK 1m	-SEK 85m

보상 대 시장: Morten 의 총 보상 ($USD 721.85K )은 German 시장( $USD 472.15K ).

보상과 수익: 회사가 수익성이 없는 동안 Morten 의 보상이 증가했습니다.

CEO

Morten Henneveld (48 yo)

4.2yrs

테뉴어

SEK 7,939,000

보상

Mr. Morten Henneveld has been Chief Executive Officer at OssDsign AB (publ) since September 1, 2020. Mr. Henneveld serves as a Director at Sime Diagnostics Ltd., since October 2022. He is Senior Vice Presi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Morten Henneveld	Chief Executive Officer	4.2yrs	SEK 7.94m	0.20% € 144.9k
Anders Svensson	Chief Financial Officer	4yrs	데이터 없음	0.085% € 60.1k
Tom Buckland	Chief Technical Officer	less than a year	데이터 없음	데이터 없음
Melanie Marshall	Vice President of Clinical & Medical Affairs	2.8yrs	데이터 없음	데이터 없음
Eric Patermo	Vice President of Sales US	4.8yrs	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: 5J6 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Viktor Drvota	Independent Director	9.8yrs	데이터 없음	데이터 없음
Newton Aguiar	Independent Director	5.8yrs	SEK 250.00	0.10% € 72.3k
Simon Cartmell	Independent Chairman of the Board	8.6yrs	SEK 350.00	0.13% € 90.6k
Jill Schiaparelli	Independent Director	2.4yrs	SEK 250.00	데이터 없음
Christer Fahraeus	Director	less than a year	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 이사회: 5J6 의 이사회는 경험(평균 재직 기간 5.8 년)으로 간주됩니다.

OssDsign 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

OssDsign AB (publ), Annual General Meeting, May 21, 2024

High number of new directors

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: kr0.10 loss per share (vs kr0.50 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.30 loss in 2Q 2023)

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings released: kr0.10 loss per share (vs kr0.30 loss in 1Q 2023)

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

Forecast breakeven date moved forward to 2024

Full year 2023 earnings released: kr1.60 loss per share (vs kr1.70 loss in FY 2022)

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Now 22% undervalued

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Forecast breakeven date moved forward to 2024

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

No longer forecast to breakeven

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.30 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.40 loss per share (vs kr0.40 loss in 2Q 2021)

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

First quarter 2022 earnings released: kr0.40 loss per share (vs kr1.10 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020)

Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million.

New Scientific Paper Further Confirms Osteointegration of OssDsign Cranial PSI Implants

First quarter 2021 earnings released: kr1.10 loss per share (vs kr1.00 loss in 1Q 2020)

Anders Svensson Joins OssDsign AB (Publ) as Chief Financial Officer

OssDsign AB (publ), Annual General Meeting, Jun 04, 2021

New 90-day low: €1.35

Full year 2020 earnings released: kr4.40 loss per share (vs kr5.46 loss in FY 2019)

Revenue misses expectations

OssDsign AB (publ) Announces New Clinical Data from 1,055 Cranioplasty Procedures

New 90-day low: €1.36

Chairman of the Board recently bought €26k worth of stock

Svensson's CFO Claes Lindblad Is Leaving the Company

Third quarter 2020 earnings released: kr1.10 loss per share

Revenue misses expectations

OssDsign AB (publ) to Report Fiscal Year 2020 Results on Feb 17, 2021

New 90-day low: €1.42

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.169392 million.

Earnings released

OssDsign AB (publ) Announces Chief Executive Officer Changes

CEO 보상 분석

CEO

테뉴어

보상